Across TCGA pan-cancer cohorts, GPR22 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GPR22 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in brain lower grade glioma (LGG), where higher GPR22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPR22 expression acts as an unfavorable survival marker.
LGG and UCEC are the cancer types where GPR22 Mutation most reproducibly stratifies survival.